Nanotargeting of Drug(s) for Delaying Dementia: Relevance of Covid-19 Impact on Dementia

American Journal of Alzheimer’s Disease &Other Dementiasr, Volume 35, Issue , January-December 2020.
By incorporating appropriate drug(s) into lipid (biobased) nanocarriers, one obtains a combination therapeutic for dementia treatment that targets certain cell-surface scavenger receptors (mainly class B type I, or “SR-BI”) and thereby crosses the blood-brain barrier. The cardiovascular risk factors for dementia trigger widespread inflammation — which lead to neurodegeneration, gradual cognitive/memory decline, and eventually (late-onset) dementia. Accordingly, one useful strategy to delay dementia could be based upon nanotargeting drug(s), using lipid nanocarriers, toward a major receptor class responsible for inflammation-associated (cytokine-mediated) cell signaling events. At the same time, the immune response and excessive inflammation, commonly observed in the very recent human coronavirus (COVID-19) pandemic, may accelerate the progression of brain inflammatory neurodegeneration—which increases the probability of post-infection memory impairment and accelerating progression of Alzheimer’s disease. Hence, the proposed multitasking combination therapeutic, using a (biobased) lipid nanocarrier, may also display greater effectiveness at different stages of dementia.Nanotargeting of Drug(s) for Delaying Dementia: Relevance of Covid-19 Impact on DementiaNanotargeting of Drug(s) for Delaying Dementia: Relevance of Covid-19 Impact on DementiaAlzheimers{$excerpt:n}